ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

DCTH Delcath Systems Inc

4.77
-0.32 (-6.29%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 393,178
Bid Price 4.72
Ask Price 4.95
News -
Day High 5.05

Low
2.25

52 Week Range

High
7.99

Day Low 4.75
Share Name Share Symbol Market Stock Type
Delcath Systems Inc DCTH NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.32 -6.29% 4.77 19:00:00
Open Price Low Price High Price Close Price Previous Close
5.03 4.75 5.05 4.77 5.09
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
2,725 393,178 US$ 4.86 US$ 1,911,926 - 2.25 - 7.99
Last Trade Type Quantity Price Currency
18:24:06 3 US$ 4.77 USD

Delcath Systems Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
105.38M 22.05M - 2.72M -36.51M -1.66 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Delcath Systems News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DCTH Message Board. Create One! See More Posts on DCTH Message Board See More Message Board Posts

Historical DCTH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.515.154.374.81413,2320.265.76%
1 Month4.225.153.704.34243,2210.5513.03%
3 Months4.065.153.704.36216,8470.7117.49%
6 Months4.065.152.253.61288,1300.7117.49%
1 Year5.887.992.255.11728,129-1.11-18.88%
3 Years16.8321.002.255.80285,253-12.06-71.66%
5 Years3.7725.182.256.54237,6201.0026.53%

Delcath Systems Description

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Your Recent History

Delayed Upgrade Clock